How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

(NASDAQ:ARGX – Free Report) had its price target lifted by Piper Sandler from $620.00 to $725.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has ...

Central Pacific Bank Trust Division bought a new position in argenx SE (NASDAQ:ARGX – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The ...

FY25 consensus $4.69. Raises FY25 revenue view to $1.15B-$1.225B from $1.095B-$1.17B, consensus $1.16B.Stay Ahead of the Market:Discover ...